QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, October 1, 2003, 23(26):8844-8853

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (54) Citing Articles via Google Scholar Google Scholar Articles by Cirrito, J. R. Articles by Holtzman, D. M. Search for Related Content PubMed PubMed Citation Articles by Cirrito, J. R. Articles by Holtzman, D. M.

 Previous Article  |  Next Article 

Cellular/Molecular
In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid- Metabolism and Half-Life

John R. Cirrito,¹ Patrick C. May,⁴ Mark A. O'Dell,¹ Jennie W. Taylor,¹ Maia Parsadanian,¹ Jeffrey W. Cramer,⁵ James E. Audia,⁶ Jeffrey S. Nissen,⁶ Kelly R. Bales,⁴ Steven M. Paul,^4,7 Ronald B. DeMattos,⁴ and David M. Holtzman^1,2,3

Departments of ¹Neurology and ²Molecular Biology and Pharmacology and ³Center for the Study of Nervous System Injury, Washington University School of Medicine, St. Louis, Missouri 63110, ⁴Neuroscience Discovery Research and ⁵Drug Disposition-Lead Optimization, ⁶Discovery Chemistry Research, Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana 46285, and ⁷Departments of Pharmacology, Toxicology, and Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana 46285

Soluble amyloid- (A) peptide converts to structures with high -sheet content in Alzheimer's disease (AD). Soluble A is released by neurons into the brain interstitial fluid (ISF), in which it can convert into toxic aggregates. Because assessment of ISF A levels may provide unique insights into A metabolism and AD, an in vivo microdialysis technique was developed to measure it. Our A microdialysis technique was validated ex vivo with human CSF and then in vivo in awake, freely moving mice. Using human amyloid precursor protein (APP) transgenic mice, we found that, before the onset of AD-like pathology, ISF A in hippocampus and cortex correlated with levels of APP in those tissues. After the onset of A deposition, significant changes in the ISF A₄₀/A₄₂ ratio developed without changes in A_1-x. These changes differed from changes seen in tissue lysates from the same animals. By rapidly inhibiting A production, we found that ISF A half-life was short (2 hr) in young mice but was twofold longer in mice with A deposits. This increase in half-life, without an increase in steady-state levels, suggests that inhibition of A synthesis reveals a portion of the insoluble A pool that is in dynamic equilibrium with ISF A. This now measurable in vivo pool is a likely target for new diagnostic and therapeutic strategies.

Key words: Alzheimer; amyloid; interstitial fluid; microdialysis; half-life; gamma-secretase

---

Received June 11, 2003; revised August 4, 2003; accepted August 4, 2003.

This article has been cited by other articles:

				J. E. Meredith Jr., L. A. Thompson, J. H. Toyn, L. Marcin, D. M. Barten, J. Marcinkeviciene, L. Kopcho, Y. Kim, A. Lin, V. Guss, et al. P-Glycoprotein Efflux and Other Factors Limit Brain Amyloid {beta} Reduction by {beta}-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitors in Mice J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 502 - 513. [Abstract] [Full Text] [PDF]

				S. Sankaranarayanan, E. A. Price, G. Wu, M.-C. Crouthamel, X.-P. Shi, K. Tugusheva, K. X. Tyler, J. Kahana, J. Ellis, L. Jin, et al. In Vivo {beta}-Secretase 1 Inhibition Leads to Brain A{beta} Lowering and Increased {alpha}-Secretase Processing of Amyloid Precursor Protein without Effect on Neuregulin-1 J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 957 - 969. [Abstract] [Full Text] [PDF]

				T. Bolmont, F. Clavaguera, M. Meyer-Luehmann, M. C. Herzig, R. Radde, M. Staufenbiel, J. Lewis, M. Hutton, M. Tolnay, and M. Jucker Induction of Tau Pathology by Intracerebral Infusion of Amyloid- -Containing Brain Extract and by Amyloid- Deposition in APP x Tau Transgenic Mice Am. J. Pathol., December 1, 2007; 171(6): 2012 - 2020. [Abstract] [Full Text] [PDF]

				M. E. Goldstein, Y. Cao, T. Fiedler, J. Toyn, L. Iben, D. M. Barten, M. Pierdomenico, J. Corsa, C. V. C. Prasad, R. E. Olson, et al. Ex Vivo Occupancy of {gamma}-Secretase Inhibitors Correlates with Brain beta-Amyloid Peptide Reduction in Tg2576 Mice J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 102 - 108. [Abstract] [Full Text] [PDF]

				W. Farris, S. G. Schutz, J. R. Cirrito, G. M. Shankar, X. Sun, A. George, M. A. Leissring, D. M. Walsh, W. Q. Qiu, D. M. Holtzman, et al. Loss of Neprilysin Function Promotes Amyloid Plaque Formation and Causes Cerebral Amyloid Angiopathy Am. J. Pathol., July 1, 2007; 171(1): 241 - 251. [Abstract] [Full Text] [PDF]

				V. Gelfanova, R. E. Higgs, R. A. Dean, D. M. Holtzman, M. R. Farlow, E. R. Siemers, A. Boodhoo, Y.-W. Qian, X. He, Z. Jin, et al. Quantitative analysis of amyloid-{beta} peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry Brief Funct Genomic Proteomic, June 20, 2007; (2007) elm010v1. [Abstract] [Full Text] [PDF]

				J.-E. Kang, J. R. Cirrito, H. Dong, J. G. Csernansky, and D. M. Holtzman Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity PNAS, June 19, 2007; 104(25): 10673 - 10678. [Abstract] [Full Text] [PDF]

				A. M. Fagan, C. M. Roe, C. Xiong, M. A. Mintun, J. C. Morris, and D. M. Holtzman Cerebrospinal Fluid tau/beta-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults Arch Neurol, March 1, 2007; 64(3): 343 - 349. [Abstract] [Full Text] [PDF]

				R. J. Bateman, G. Wen, J. C. Morris, and D. M. Holtzman Fluctuations of CSF amyloid-ss levels: Implications for a diagnostic and therapeutic biomarker Neurology, February 27, 2007; 68(9): 666 - 669. [Abstract] [Full Text] [PDF]

				Y. Levites, L. A. Smithson, R. W. Price, R. S. Dakin, B. Yuan, M. R. Sierks, J. Kim, E. McGowan, D. K. Reed, T. L. Rosenberry, et al. Insights into the mechanisms of action of anti-A{beta} antibodies in Alzheimer's disease mouse models FASEB J, December 1, 2006; 20(14): 2576 - 2578. [Abstract] [Full Text] [PDF]

				T. A. Lanz, M. J. Karmilowicz, K. M. Wood, N. Pozdnyakov, P. Du, M. A. Piotrowski, T. M. Brown, C. E. Nolan, K. E. G. Richter, J. E. Finley, et al. Concentration-Dependent Modulation of Amyloid-beta in Vivo and in Vitro Using the {gamma}-Secretase Inhibitor, LY-450139 J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 924 - 933. [Abstract] [Full Text] [PDF]

				K.-J. Yin, J. R. Cirrito, P. Yan, X. Hu, Q. Xiao, X. Pan, R. Bateman, H. Song, F.-F. Hsu, J. Turk, et al. Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-beta Peptide Catabolism J. Neurosci., October 25, 2006; 26(43): 10939 - 10948. [Abstract] [Full Text] [PDF]

				E. B. Lee, L. Z. Leng, B. Zhang, L. Kwong, J. Q. Trojanowski, T. Abel, and V. M.-Y. Lee Targeting Amyloid-beta Peptide (Abeta) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Abeta Precursor Protein (APP) Transgenic Mice J. Biol. Chem., February 17, 2006; 281(7): 4292 - 4299. [Abstract] [Full Text] [PDF]

				K. K. Kandimalla, G. L. Curran, S. S. Holasek, E. J. Gilles, T. M. Wengenack, and J. F. Poduslo Pharmacokinetic Analysis of the Blood-Brain Barrier Transport of 125I-Amyloid {beta} Protein 40 in Wild-Type and Alzheimer's Disease Transgenic Mice (APP,PS1) and Its Implications for Amyloid Plaque Formation J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1370 - 1378. [Abstract] [Full Text] [PDF]

				J. D. Fryer, K. Simmons, M. Parsadanian, K. R. Bales, S. M. Paul, P. M. Sullivan, and D. M. Holtzman Human Apolipoprotein E4 Alters the Amyloid-{beta} 40:42 Ratio and Promotes the Formation of Cerebral Amyloid Angiopathy in an Amyloid Precursor Protein Transgenic Model J. Neurosci., March 16, 2005; 25(11): 2803 - 2810. [Abstract] [Full Text] [PDF]

				D. M. Barten, V. L. Guss, J. A. Corsa, A. Loo, S. B. Hansel, M. Zheng, B. Munoz, K. Srinivasan, B. Wang, B. J. Robertson, et al. Dynamics of {beta}-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of {beta}-Amyloid Precursor Protein Transgenic Mice Treated with a {gamma}-Secretase Inhibitor J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 635 - 643. [Abstract] [Full Text] [PDF]

				R. Deane, Z. Wu, and B. V. Zlokovic RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid {beta}-Peptide Clearance Through Transport Across the Blood-Brain Barrier Stroke, November 1, 2004; 35(11_suppl_1): 2628 - 2631. [Abstract] [Full Text] [PDF]

				T. A. Lanz, J. D. Hosley, W. J. Adams, and K. M. Merchant Studies of A{beta} Pharmacodynamics in the Brain, Cerebrospinal Fluid, and Plasma in Young (Plaque-Free) Tg2576 Mice Using the {gamma}-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575) J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 49 - 55. [Abstract] [Full Text]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help